301 related articles for article (PubMed ID: 25262914)
1. Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
Resnier P; LeQuinio P; Lautram N; André E; Gaillard C; Bastiat G; Benoit JP; Passirani C
Biotechnol J; 2014 Nov; 9(11):1389-401. PubMed ID: 25262914
[TBL] [Abstract][Full Text] [Related]
2. Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse.
Resnier P; Galopin N; Sibiril Y; Clavreul A; Cayon J; Briganti A; Legras P; Vessières A; Montier T; Jaouen G; Benoit JP; Passirani C
Pharmacol Res; 2017 Dec; 126():54-65. PubMed ID: 28159700
[TBL] [Abstract][Full Text] [Related]
3. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro.
Resnier P; David S; Lautram N; Delcroix GJ; Clavreul A; Benoit JP; Passirani C
Int J Pharm; 2013 Oct; 454(2):748-55. PubMed ID: 23583841
[TBL] [Abstract][Full Text] [Related]
4. siRNA LNCs--a novel platform of lipid nanocapsules for systemic siRNA administration.
David S; Resnier P; Guillot A; Pitard B; Benoit JP; Passirani C
Eur J Pharm Biopharm; 2012 Jun; 81(2):448-52. PubMed ID: 22381204
[TBL] [Abstract][Full Text] [Related]
5. Tumor transfection after systemic injection of DNA lipid nanocapsules.
Morille M; Passirani C; Dufort S; Bastiat G; Pitard B; Coll JL; Benoit JP
Biomaterials; 2011 Mar; 32(9):2327-33. PubMed ID: 21185595
[TBL] [Abstract][Full Text] [Related]
6. Characterization and comparison of two novel nanosystems associated with siRNA for cellular therapy.
André EM; Pensado A; Resnier P; Braz L; Rosa da Costa AM; Passirani C; Sanchez A; Montero-Menei CN
Int J Pharm; 2016 Jan; 497(1-2):255-67. PubMed ID: 26617318
[TBL] [Abstract][Full Text] [Related]
7. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.
Belletti D; Tosi G; Forni F; Lagreca I; Barozzi P; Pederzoli F; Vandelli MA; Riva G; Luppi M; Ruozi B
Eur J Pharm Biopharm; 2016 Feb; 99():7-17. PubMed ID: 26625717
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study.
Khatri N; Baradia D; Vhora I; Rathi M; Misra A
AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330
[TBL] [Abstract][Full Text] [Related]
9. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
10. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting.
Morille M; Passirani C; Letrou-Bonneval E; Benoit JP; Pitard B
Int J Pharm; 2009 Sep; 379(2):293-300. PubMed ID: 19505548
[TBL] [Abstract][Full Text] [Related]
11. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
12. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
Morille M; Montier T; Legras P; Carmoy N; Brodin P; Pitard B; Benoît JP; Passirani C
Biomaterials; 2010 Jan; 31(2):321-9. PubMed ID: 19800113
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133.
Bourseau-Guilmain E; Béjaud J; Griveau A; Lautram N; Hindré F; Weyland M; Benoit JP; Garcion E
Int J Pharm; 2012 Feb; 423(1):93-101. PubMed ID: 21683129
[TBL] [Abstract][Full Text] [Related]
15. Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and
Resnier P; Lepeltier E; Emina AL; Galopin N; Bejaud J; David S; Ballet C; Benvegnu T; Pecorari F; Chourpa I; Benoit JP; Passirani C
RSC Adv; 2019 Aug; 9(47):27264-27278. PubMed ID: 35529231
[TBL] [Abstract][Full Text] [Related]
16. VCAM-1 specific PEGylated SAINT-based lipoplexes deliver siRNA to activated endothelium in vivo but do not attenuate target gene expression.
Leus NG; Morselt HW; Zwiers PJ; Kowalski PS; Ruiters MH; Molema G; Kamps JA
Int J Pharm; 2014 Jul; 469(1):121-31. PubMed ID: 24746643
[TBL] [Abstract][Full Text] [Related]
17. A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy.
Zhang L; Tian B; Li Y; Lei T; Meng J; Yang L; Zhang Y; Chen F; Zhang H; Xu H; Zhang Y; Tang X
ACS Appl Mater Interfaces; 2015 Nov; 7(45):25147-61. PubMed ID: 26501354
[TBL] [Abstract][Full Text] [Related]
18. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
[TBL] [Abstract][Full Text] [Related]
19. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
20. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness.
Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G
Eur J Pharm Sci; 2016 Oct; 93():493-503. PubMed ID: 27593989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
